This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
ARIAD Pharma Stock Gains on Acquisition Deal with Takeda
by Zacks Equity Research
ARIAD Pharmaceuticals, Inc.'s (ARIA) shares surged 72.8% after the company announced a definitive agreement to be acquired by Japan-based Takeda Pharmaceutical Company Limited (TKPYY) for approximately $5.2 billion.
Halozyme Therapeutics (HALO) in Focus: Stock Up 6.4%
by Zacks Equity Research
Halozyme Therapeutics, Inc. (HALO) saw its shares rise above 6% in the last trading session.
5 Small Cap ETFs and Stocks to Play January & Trump Effect
by Sweta Killa
Small caps would enjoy the dual tailwinds of the January Effect and Trump policies.
New Strong Buy Stocks for December 29th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday
5 Reasonable Breakout Stocks for Exceptional Returns
by Swarup Gupta
If properly implemented, such a strategy could deliver impressive returns.
5 Top Performing Biotechnology Stocks of November
by Zacks Equity Research
November was a great month for pharma/biotech stocks after a rather difficult year when the industry struggled with media and political focus on high drug prices.
The Zacks Analyst Blog Highlights: Enzo Biochem, Exelixis, Genmab A/S, Heska and Incyte
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Enzo Biochem, Exelixis, Genmab A/S, Heska and Incyte
Zacks.com featured highlights: include Cambrex, Enzo Biochem, Alliqua BioMedical, CubeSmart and Snap-on
by Zacks Equity Research
Zacks.com featured highlights: include Cambrex, Enzo Biochem, Alliqua BioMedical, CubeSmart and Snap-on
New Strong Buy Stocks for July 11th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Monday